Patients curatively treated for CRC in stages I–III or in stage III with moderate to high intensity of immunoreactivity for GDF15 had a higher recurrence rate and shorter time to recurrence compared with patients with no or low intensity for GDF15 (Figures 2A and B). This evidence concerns the gene GDF15 and colorectal carcinoma.